Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083

Journal:

Clinical Infectious Diseases

Published:

2025-07-01

DOI:

10.1093/cid/ciaf221

Affiliations:

10

Authors:

13

Go to article

Institutions	Authors	Share
Fred Hutchinson Cancer Center, United States of America (USA)	3.000000	0.23
Johns Hopkins University (JHU), United States of America (USA)	2.000000	0.15
Institute of HIV Research and Innovation (IHRI), Thailand	1.000000	0.08
University of São Paulo (USP), Brazil	1.000000	0.08
AstraZeneca Gaithersburg, MD, United States of America (USA)	1.000000	0.08
Gilead, United States of America (USA)	1.000000	0.08
ViiV Healthcare Company USA, United States of America (USA)	1.000000	0.08
FHI 360, United States of America (USA)	1.000000	0.08
Oswaldo Cruz Foundation (FIOCRUZ), Brazil	1.000000	0.08
UCLA Health, United States of America (USA)	1.000000	0.08

Interested in Clinical Sciences?